Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aclaris Therapeutics (ACRS) Receivables - Other (2017 - 2021)

Historic Receivables - Other for Aclaris Therapeutics (ACRS) over the last 4 years, with Q4 2021 value amounting to $24000.0.

  • Aclaris Therapeutics' Receivables - Other fell 9200.0% to $24000.0 in Q4 2021 from the same period last year, while for Dec 2021 it was $24000.0, marking a year-over-year decrease of 9200.0%. This contributed to the annual value of $24000.0 for FY2021, which is 9200.0% down from last year.
  • Aclaris Therapeutics' Receivables - Other amounted to $24000.0 in Q4 2021, which was down 9200.0% from $24000.0 recorded in Q3 2021.
  • Over the past 5 years, Aclaris Therapeutics' Receivables - Other peaked at $300000.0 during Q2 2020, and registered a low of -$570000.0 during Q4 2017.
  • In the last 4 years, Aclaris Therapeutics' Receivables - Other had a median value of $24000.0 in 2021 and averaged $57000.0.
  • As far as peak fluctuations go, Aclaris Therapeutics' Receivables - Other soared by 20000.0% in 2020, and later plummeted by 9200.0% in 2021.
  • Aclaris Therapeutics' Receivables - Other (Quarter) stood at -$570000.0 in 2017, then surged by 117.54% to $100000.0 in 2019, then surged by 200.0% to $300000.0 in 2020, then crashed by 92.0% to $24000.0 in 2021.
  • Its Receivables - Other stands at $24000.0 for Q4 2021, versus $24000.0 for Q3 2021 and $24000.0 for Q2 2021.